Shots:

• The P-III MOVe-OUT trial evaluates molnupiravir vs PBO in non-hospitalized adult patients with COVID-19 with 1 risk factor associated with poor disease outcomes & symptom onset within 5 days before randomization
• At the interim analysis, the therapy showed a ~50% reduction in risk of hospitalization or death; patients were hospitalized or died (7.3% vs 14.1%) @ 29Day following randomization & no deaths were reported
• The companies continue to discuss additional measures and collaborations to accelerate global access to molnupiravir. The therapy is also being evaluated in the P-III MOVe-AHEAD study as monothx. for post-exposure prophylaxis to prevent COVID-19 within households

  Ref: Merck | Image: Merck